Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
Thomas BachelotPaul-Henri CottuSylvie ChabaudFlorence DalencDjelila AllouacheSuzette DelalogeJean-Philippe JacquinJulien GrenierLaurence Venat BouvetApurna JegannathenMario CamponeFrancesco Del PianoMarc DebledAnne-Claire Hardy-BessardSylvie GiacchettiMarie-Ange Mouret-ReynierPhilippe BarthelemyLaure KaluzinskiAudrey MailliezEric LegouffeMatthew SephtonJudith M BlissJean-Luc CanonFrédérique M Penault-LlorcaJérôme LemonnierDavid A CameronFabrice AndrePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Among high-risk patients, everolimus added to adjuvant ET did not improve DFS. Tolerability was a concern, with more than half of patients stopping everolimus before study completion. Everolimus cannot be recommended in the adjuvant setting.